MaxCyte Q3 EPS $(0.05) Beats $(0.08) Estimate, Sales $10.152M Beat $7.481M Estimate
Benzinga Newsdesk 6 days ago
NewsEarningsEarnings Beats
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 58.33 percent increase over losses of $(0.12) per share from the same
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.08) by 37.5 percent. This is a 58.33 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $10.152 million which beat the analyst consensus estimate of $7.481 million by 35.71 percent. This is a 48.66 percent increase over sales of $6.829 million the same period last year.
